# Sunitinib in Never-Smokers With Lung Adenocarcinoma

> **NCT01829217** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 13 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01829217
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2017-08
- **Final completion:** 2018-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01829217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01829217, "Sunitinib in Never-Smokers With Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01829217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*